Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31463242 | 0.96 | KCNH2 (0.54) | KCNH2RYR2PDE3BPDE3ADRD2 | |
| SCHEMBL330398 | 0.96 | KCNH2 (0.54) | KCNH2RYR2PDE3BPDE3ADRD2 | |
| Hydrochloric Acid SCHEMBL3126387 | 0.94 | KCNH2 (0.53) | KCNH2RYR2PDE3BPDE3ADRD2 | |
| Hydrochloric Acid SCHEMBL29627951 | 0.94 | KCNH2 (0.53) | KCNH2RYR2PDE3BPDE3ADRD2 | |
| SCHEMBL30777884 | 0.82 | KCNH2 (0.53) | KCNH2RYR2PDE3BPDE3ADRD2 | |
| SCHEMBL26776838 | 0.82 | KCNH2 (0.53) | KCNH2RYR2PDE3BPDE3ADRD2 | |
| SCHEMBL532484 | 0.81 | CD274 (0.59) | KCNH2RYR2DRD2DRD3DRD1 | |
| SCHEMBL31070657 | 0.81 | CHRNB2 (0.48) | KCNH2RYR2CD274CHRNB2CHRNA4 | |
| SCHEMBL746109 | 0.81 | HTR2C (0.57) | KCNH2RYR2DRD2DRD3HTR2C | |
| SCHEMBL8467911 | 0.81 | CD274 (0.59) | KCNH2RYR2DRD2DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10125144-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20160237095-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2016-08-18 | — | — | US | disclosed |
| EP-3055301-A1 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015157556-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015054317-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237095-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | KCNH2 2534/4885RYR2 2978/4885PDE3B 243/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | KCNH2 1359/4885RYR2 1722/4885PDE3B 140/4885 |
| US-10125144-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | KCNH2 2534/4885RYR2 2978/4885PDE3B 243/4885 |
| US-20170112832-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOA | KCNH2 4312/4885RYR2 3646/4885PDE3B 276/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | KCNH2 3852/4885RYR2 3863/4885PDE3B 243/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | KCNH2 4312/4885RYR2 3646/4885PDE3B 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.